US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TRAWS PHARMA

0.5600

+0.03005.66%

Pre-market: 0.57080.0108+1.93%07:00 EDT

Volume:76.50K

Turnover:41.56K

Market Cap:8.61M

PE:-0.38

High:0.5650

Open:0.5551

Low:0.5300

Close:0.5300

52wk High:3.27

52wk Low:0.4301

Shares:15.37M

Float Shares:12.18M

Volume Ratio:0.56

T/O Rate:0.63%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4733

EPS(LYR):0.8343

ROE:-433.36%

ROA:-99.40%

PB:5.09

PE(LYR):0.67

Loading ...

Overview Company News Filings

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

THOMSON REUTERS

OrbiMed Advisors acquires 597,729 Traws Pharma shares worth $998,207

Traws Pharma Inc reports results for the quarter ended December 31 - Earnings Summary

Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate

Benzinga Earnings

Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million

Traws Pharma Announces up to $60 Million Private Placement Financing

THOMSON REUTERS

Traws Pharma Inc - Financing Advances Co's Influenza Program Through a Human Challenge Trial for Tivoxavir Marboxil in United Kingdom

THOMSON REUTERS

Press Release: Traws Pharma Announces Up to $60 Million Private Placement Financing

Traws Pharma Inc - Announces Pricing of Private Placement for 6 Mln Common Shares - SEC Filing

THOMSON REUTERS

Traws Pharma prices unregistered $10 million PIPE at $1.67 per share

Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement

Traws Pharma delays annual report filing, seeks 15-day extension

Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview

BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold

BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients

Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

THOMSON REUTERS

Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind

THOMSON REUTERS

Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TRAW/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TRAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":0.56,"timestamp":1787601600000,"preClose":0.53,"halted":0,"volume":76500,"hourTrading":{"tag":"盘前","latestPrice":0.5708,"preClose":0.56,"latestTime":"07:00 EDT","volume":537,"amount":305.3271915,"timestamp":1787655656187,"change":0.0108,"changeRate":0.019286,"amplitude":0.059286},"delay":0,"changeRate":0.05660377358490571,"floatShares":12179546,"shares":15368277,"eps":-1.473278,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"08-25 08:53:45 EDT","open":0.5551,"high":0.565,"low":0.53,"amount":41562.7407,"amplitude":0.066038,"askPrice":0.58,"askSize":2,"bidPrice":0.52,"bidSize":42,"shortable":3,"etf":0,"ttmEps":-1.473278,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":0.56,"preHourTrading":{"tag":"盘前","latestPrice":0.5708,"preClose":0.56,"latestTime":"07:00 EDT","volume":537,"amount":305.3271915,"timestamp":1787655656187,"change":0.0108,"changeRate":0.019286,"amplitude":0.059286},"postHourTrading":{"tag":"盘后","latestPrice":0.549,"preClose":0.56,"latestTime":"19:54 EDT","volume":400,"amount":220.58098,"timestamp":1787615653574,"change":-0.011,"changeRate":-0.019643,"amplitude":0.019643},"volumeRatio":0.5552813426275015,"impliedVol":1.6331,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAW\",,,,,undefined,":{"symbol":"TRAW","floatShares":12179546,"roa":"-99.40%","roe":"-433.36%","lyrEps":0.834328,"volumeRatio":0.5552813426275015,"shares":15368277,"dividePrice":0,"high":0.565,"amplitude":0.066038,"preClose":0.53,"low":0.53,"week52Low":0.4301,"pbRate":"5.09","week52High":3.265,"institutionHeld":0,"latestPrice":0.56,"committee":0.909091,"eps":-1.473278,"divideRate":0,"volume":76500,"delay":0,"ttmEps":-1.473278,"open":0.5551,"prevYearClose":1.13,"prevWeekClose":0.53,"prevMonthClose":0.45,"prevQuarterClose":0.8433,"fiveDayClose":0.54,"twentyDayClose":0.52,"sixtyDayClose":1.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"TRAW","fiscalQuarterEnding":"2026/06","expectedEps":-0.22,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-0.16},{"market":"US","date":"2026-05-15","symbol":"TRAW","fiscalQuarterEnding":"2026/03","expectedEps":-0.92,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2026-04-15","symbol":"TRAW","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1776225600000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-11-13","symbol":"TRAW","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2025-08-14","symbol":"TRAW","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAW\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1782014400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAW\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAW","date":"2026-08-21","current":-0.262315,"percent":0.530329,"low":-1.693158,"twenty":-0.958635,"median":-0.452257,"eighty":-0.064655,"high":2.414702,"avg":-0.439737,"sd":0.609513,"marketCap":7918730},"quantilePoints":[{"date":"2024-04-05","current":-0.930105,"twenty":-0.930105,"median":-0.930105,"eighty":-0.930105,"marketCap":17623624},{"date":"2024-04-12","current":-0.875242,"twenty":-0.899279,"median":-0.879971,"eighty":-0.87246,"marketCap":16584087},{"date":"2024-04-19","current":-0.774197,"twenty":-0.884701,"median":-0.859217,"eighty":-0.774642,"marketCap":14669484},{"date":"2024-04-26","current":-0.703922,"twenty":-0.875242,"median":-0.784323,"eighty":-0.745597,"marketCap":13337908},{"date":"2024-05-03","current":-0.713993,"twenty":-0.87246,"median":-0.75973,"eighty":-0.713993,"marketCap":13528735},{"date":"2024-05-10","current":-0.722239,"twenty":-0.859217,"median":-0.743093,"eighty":-0.71377,"marketCap":13684982},{"date":"2024-05-17","current":-0.7463,"twenty":-0.799236,"median":-0.738475,"eighty":-0.713993,"marketCap":13549821},{"date":"2024-05-24","current":-0.73457,"twenty":-0.794005,"median":-0.741761,"eighty":-0.718444,"marketCap":13336853},{"date":"2024-05-31","current":-0.675921,"twenty":-0.778515,"median":-0.736522,"eighty":-0.713681,"marketCap":12272014},{"date":"2024-06-07","current":-0.836261,"twenty":-0.794624,"median":-0.73457,"eighty":-0.711322,"marketCap":15183160},{"date":"2024-06-14","current":-0.873049,"twenty":-0.83888,"median":-0.740589,"eighty":-0.71288,"marketCap":15851082},{"date":"2024-06-21","current":-0.649387,"twenty":-0.836845,"median":-0.738475,"eighty":-0.709541,"marketCap":11790270},{"date":"2024-06-28","current":-0.62709,"twenty":-0.83835,"median":-0.738475,"eighty":-0.706993,"marketCap":11385454},{"date":"2024-07-05","current":-0.557395,"twenty":-0.836651,"median":-0.734469,"eighty":-0.698614,"marketCap":10120072},{"date":"2024-07-12","current":-0.483661,"twenty":-0.814046,"median":-0.728873,"eighty":-0.672205,"marketCap":8781358},{"date":"2024-07-15","current":-0.554747,"twenty":-0.806641,"median":-0.726171,"eighty":-0.663181,"marketCap":10071990},{"date":"2024-08-02","current":-0.532446,"twenty":-0.799236,"median":-0.724978,"eighty":-0.649387,"marketCap":9667086},{"date":"2024-08-09","current":-0.491259,"twenty":-0.797102,"median":-0.722239,"eighty":-0.600613,"marketCap":8919304},{"date":"2024-08-16","current":-0.066488,"twenty":-0.794005,"median":-0.718444,"eighty":-0.532446,"marketCap":9112137},{"date":"2024-08-23","current":-0.065565,"twenty":-0.774642,"median":-0.71377,"eighty":-0.508851,"marketCap":8985580},{"date":"2024-08-30","current":-0.06743,"twenty":-0.774197,"median":-0.709986,"eighty":-0.494812,"marketCap":9241226},{"date":"2024-09-06","current":-0.06538,"twenty":-0.762623,"median":-0.702951,"eighty":-0.490604,"marketCap":8960268},{"date":"2024-09-13","current":-0.062794,"twenty":-0.758648,"median":-0.694503,"eighty":-0.071087,"marketCap":8605907},{"date":"2024-09-20","current":-0.057254,"twenty":-0.751084,"median":-0.683063,"eighty":-0.068232,"marketCap":7846562},{"date":"2024-09-27","current":-0.081301,"twenty":-0.74722,"median":-0.649387,"eighty":-0.067774,"marketCap":11142278},{"date":"2024-10-04","current":-0.073971,"twenty":-0.746382,"median":-0.624791,"eighty":-0.068232,"marketCap":10137646},{"date":"2024-10-11","current":-0.065174,"twenty":-0.745738,"median":-0.557395,"eighty":-0.067596,"marketCap":8932088},{"date":"2024-10-18","current":-0.062642,"twenty":-0.744673,"median":-0.543597,"eighty":-0.067316,"marketCap":8585034},{"date":"2024-10-25","current":-0.111702,"twenty":-0.743234,"median":-0.515682,"eighty":-0.066488,"marketCap":15308680},{"date":"2024-10-31","current":-0.109715,"twenty":-0.741526,"median":-0.508851,"eighty":-0.066652,"marketCap":15036392},{"date":"2024-11-08","current":-0.111592,"twenty":-0.739321,"median":-0.498158,"eighty":-0.06682,"marketCap":15293553},{"date":"2024-11-15","current":-0.123204,"twenty":-0.736132,"median":-0.492107,"eighty":-0.067201,"marketCap":16884930},{"date":"2024-11-22","current":-0.096923,"twenty":-0.734509,"median":-0.489621,"eighty":-0.06743,"marketCap":13645248},{"date":"2024-11-29","current":-0.098427,"twenty":-0.734469,"median":-0.48099,"eighty":-0.067496,"marketCap":13857037},{"date":"2024-12-06","current":-0.108407,"twenty":-0.733312,"median":-0.130241,"eighty":-0.067596,"marketCap":15262104},{"date":"2024-12-13","current":-0.104014,"twenty":-0.729414,"median":-0.121316,"eighty":-0.067685,"marketCap":14643681},{"date":"2024-12-20","current":-0.114642,"twenty":-0.725217,"median":-0.114642,"eighty":-0.068025,"marketCap":16139817},{"date":"2024-12-27","current":-0.244993,"twenty":-0.723719,"median":-0.117501,"eighty":-0.068353,"marketCap":34491315},{"date":"2025-01-03","current":-0.186323,"twenty":-0.723452,"median":-0.123204,"eighty":-0.068427,"marketCap":26231553},{"date":"2025-01-10","current":-0.173429,"twenty":-0.722482,"median":-0.130241,"eighty":-0.069344,"marketCap":24416220},{"date":"2025-01-17","current":-0.146996,"twenty":-0.721141,"median":-0.147157,"eighty":-0.069786,"marketCap":20694789},{"date":"2025-01-24","current":-0.13797,"twenty":-0.719413,"median":-0.140763,"eighty":-0.070056,"marketCap":19424056},{"date":"2025-01-31","current":-0.156666,"twenty":-0.718444,"median":-0.146996,"eighty":-0.070643,"marketCap":22056288},{"date":"2025-02-07","current":-0.178157,"twenty":-0.715773,"median":-0.153981,"eighty":-0.07105,"marketCap":25081842},{"date":"2025-02-14","current":-0.173739,"twenty":-0.713859,"median":-0.157526,"eighty":-0.072709,"marketCap":24459897},{"date":"2025-02-21","current":-0.121618,"twenty":-0.713592,"median":-0.156666,"eighty":-0.073848,"marketCap":17121928},{"date":"2025-02-28","current":-0.087129,"twenty":-0.71288,"median":-0.149414,"eighty":-0.074131,"marketCap":12266456},{"date":"2025-03-07","current":-0.070533,"twenty":-0.710432,"median":-0.144632,"eighty":-0.071013,"marketCap":9929988},{"date":"2025-03-14","current":-0.07157,"twenty":-0.706225,"median":-0.135069,"eighty":-0.071013,"marketCap":10076017},{"date":"2025-03-21","current":-0.074682,"twenty":-0.703145,"median":-0.130241,"eighty":-0.070984,"marketCap":10514105},{"date":"2025-03-28","current":-0.066643,"twenty":-0.70173,"median":-0.123448,"eighty":-0.070533,"marketCap":9382378},{"date":"2025-04-04","current":-0.066422,"twenty":-0.698614,"median":-0.121618,"eighty":-0.069679,"marketCap":11060862},{"date":"2025-04-11","current":-0.053321,"twenty":-0.692996,"median":-0.117957,"eighty":-0.068372,"marketCap":8879132},{"date":"2025-04-17","current":-0.060633,"twenty":-0.690629,"median":-0.115407,"eighty":-0.067596,"marketCap":10096842},{"date":"2025-04-25","current":-0.046618,"twenty":-0.687348,"median":-0.111751,"eighty":-0.066971,"marketCap":7762898},{"date":"2025-05-02","current":-0.042961,"twenty":-0.674063,"median":-0.111618,"eighty":-0.066488,"marketCap":7154043},{"date":"2025-05-09","current":-0.042657,"twenty":-0.663181,"median":-0.111481,"eighty":-0.065417,"marketCap":7103306},{"date":"2025-05-16","current":-0.033516,"twenty":-0.647743,"median":-0.11053,"eighty":-0.064788,"marketCap":5581169},{"date":"2025-05-23","current":-0.045648,"twenty":-0.63835,"median":-0.110157,"eighty":-0.064588,"marketCap":6392975},{"date":"2025-05-30","current":-0.055226,"twenty":-0.62709,"median":-0.109384,"eighty":-0.063348,"marketCap":7734397},{"date":"2025-06-06","current":-0.058802,"twenty":-0.622492,"median":-0.108696,"eighty":-0.062794,"marketCap":8235186},{"date":"2025-06-13","current":-0.071516,"twenty":-0.600613,"median":-0.107668,"eighty":-0.063175,"marketCap":10015767},{"date":"2025-06-20","current":-0.065556,"twenty":-0.566039,"median":-0.107023,"eighty":-0.063313,"marketCap":9181119},{"date":"2025-06-27","current":-0.056815,"twenty":-0.557298,"median":-0.10387,"eighty":-0.062794,"marketCap":7956970},{"date":"2025-07-03","current":-0.05761,"twenty":-0.555758,"median":-0.101756,"eighty":-0.062399,"marketCap":8068256},{"date":"2025-07-11","current":-0.062378,"twenty":-0.541366,"median":-0.099933,"eighty":-0.061976,"marketCap":8735974},{"date":"2025-07-18","current":-0.064364,"twenty":-0.529937,"median":-0.097675,"eighty":-0.061583,"marketCap":9014190},{"date":"2025-07-25","current":-0.064761,"twenty":-0.520715,"median":-0.095947,"eighty":-0.061819,"marketCap":9069833},{"date":"2025-08-01","current":-0.061186,"twenty":-0.513446,"median":-0.092228,"eighty":-0.061583,"marketCap":8569045},{"date":"2025-08-08","current":-0.058802,"twenty":-0.510093,"median":-0.087897,"eighty":-0.061164,"marketCap":8235186},{"date":"2025-08-15","current":-0.50579,"twenty":-0.507369,"median":-0.086481,"eighty":-0.061164,"marketCap":9014190},{"date":"2025-08-22","current":-0.546969,"twenty":-0.527596,"median":-0.090759,"eighty":-0.061186,"marketCap":9748084},{"date":"2025-08-29","current":-0.562823,"twenty":-0.55008,"median":-0.094773,"eighty":-0.061424,"marketCap":10030637},{"date":"2025-09-05","current":-0.65993,"twenty":-0.557347,"median":-0.096218,"eighty":-0.061583,"marketCap":11761275},{"date":"2025-09-12","current":-0.717402,"twenty":-0.561238,"median":-0.098427,"eighty":-0.061583,"marketCap":12785530},{"date":"2025-09-19","current":-0.81649,"twenty":-0.587397,"median":-0.100444,"eighty":-0.06174,"marketCap":14551487},{"date":"2025-09-26","current":-0.745146,"twenty":-0.633715,"median":-0.10251,"eighty":-0.061976,"marketCap":13279998},{"date":"2025-10-03","current":-0.721365,"twenty":-0.66395,"median":-0.104979,"eighty":-0.061978,"marketCap":12856168},{"date":"2025-10-10","current":-1.240589,"twenty":-0.692996,"median":-0.107234,"eighty":-0.06201,"marketCap":22109784},{"date":"2025-10-17","current":-1.058266,"twenty":-0.706225,"median":-0.108145,"eighty":-0.062128,"marketCap":18860423},{"date":"2025-10-24","current":-1.051562,"twenty":-0.713592,"median":-0.109053,"eighty":-0.062292,"marketCap":18740938},{"date":"2025-10-31","current":-1.05556,"twenty":-0.718444,"median":-0.109936,"eighty":-0.06243,"marketCap":18812196},{"date":"2025-11-07","current":-0.809663,"twenty":-0.722967,"median":-0.110382,"eighty":-0.062562,"marketCap":14429809},{"date":"2025-11-14","current":-0.707705,"twenty":-0.726854,"median":-0.111401,"eighty":-0.062695,"marketCap":12612722},{"date":"2025-11-21","current":-1.284879,"twenty":-0.733984,"median":-0.111592,"eighty":-0.062775,"marketCap":17100455},{"date":"2025-11-28","current":-1.621109,"twenty":-0.736689,"median":-0.111702,"eighty":-0.062779,"marketCap":21575340},{"date":"2025-12-05","current":-1.416969,"twenty":-0.741064,"median":-0.113304,"eighty":-0.062794,"marketCap":18858446},{"date":"2025-12-12","current":-1.398957,"twenty":-0.745146,"median":-0.117501,"eighty":-0.062794,"marketCap":18618720},{"date":"2025-12-19","current":-0.750513,"twenty":-0.74863,"median":-0.120524,"eighty":-0.06287,"marketCap":9988583},{"date":"2025-12-26","current":-0.744509,"twenty":-0.74911,"median":-0.123065,"eighty":-0.063175,"marketCap":9908675},{"date":"2026-01-02","current":-0.678464,"twenty":-0.74911,"median":-0.12421,"eighty":-0.063313,"marketCap":9029679},{"date":"2026-01-09","current":-0.846579,"twenty":-0.755955,"median":-0.131212,"eighty":-0.063525,"marketCap":11267122},{"date":"2026-01-16","current":-1.032707,"twenty":-0.760288,"median":-0.140763,"eighty":-0.063894,"marketCap":13744291},{"date":"2026-01-23","current":-1.495023,"twenty":-0.77433,"median":-0.145814,"eighty":-0.063975,"marketCap":19897258},{"date":"2026-01-30","current":-1.260863,"twenty":-0.780019,"median":-0.151509,"eighty":-0.064208,"marketCap":16780820},{"date":"2026-02-06","current":-1.032707,"twenty":-0.795244,"median":-0.157096,"eighty":-0.064364,"marketCap":13744291},{"date":"2026-02-13","current":-1.152789,"twenty":-0.80455,"median":-0.158601,"eighty":-0.064364,"marketCap":15342464},{"date":"2026-02-20","current":-0.942645,"twenty":-0.811381,"median":-0.160965,"eighty":-0.064364,"marketCap":12545661},{"date":"2026-02-27","current":-0.972665,"twenty":-0.836845,"median":-0.164538,"eighty":-0.064453,"marketCap":12945204},{"date":"2026-03-06","current":-0.960657,"twenty":-0.845071,"median":-0.17085,"eighty":-0.064589,"marketCap":12785387},{"date":"2026-03-13","current":-1.21283,"twenty":-0.86427,"median":-0.173584,"eighty":-0.064613,"marketCap":16141551},{"date":"2026-03-20","current":-1.308895,"twenty":-0.874365,"median":-0.178157,"eighty":-0.064655,"marketCap":17420090},{"date":"2026-03-27","current":-1.158793,"twenty":-0.891005,"median":-0.18353,"eighty":-0.06471,"marketCap":15422373},{"date":"2026-04-02","current":-0.996682,"twenty":-0.915831,"median":-0.18858,"eighty":-0.064761,"marketCap":13264839},{"date":"2026-04-10","current":-0.900616,"twenty":-0.935334,"median":-0.19492,"eighty":-0.064761,"marketCap":11986300},{"date":"2026-04-17","current":1.843869,"twenty":-0.947448,"median":-0.24725,"eighty":-0.064761,"marketCap":16908281},{"date":"2026-04-24","current":1.351347,"twenty":-0.941444,"median":-0.19406,"eighty":-0.064603,"marketCap":12391853},{"date":"2026-05-01","current":1.583956,"twenty":-0.935334,"median":-0.186216,"eighty":-0.064364,"marketCap":14524877},{"date":"2026-05-08","current":1.883025,"twenty":-0.92781,"median":-0.178666,"eighty":-0.06365,"marketCap":17267336},{"date":"2026-05-15","current":1.805488,"twenty":-0.91857,"median":-0.175166,"eighty":-0.062794,"marketCap":16556328},{"date":"2026-05-22","current":-1.162017,"twenty":-0.947448,"median":-0.178666,"eighty":-0.06287,"marketCap":22574496},{"date":"2026-05-29","current":-1.185413,"twenty":-0.960657,"median":-0.186109,"eighty":-0.063175,"marketCap":23029016},{"date":"2026-06-05","current":-1.154218,"twenty":-0.966661,"median":-0.192449,"eighty":-0.063348,"marketCap":22422990},{"date":"2026-06-12","current":-0.990444,"twenty":-0.974846,"median":-0.244993,"eighty":-0.063569,"marketCap":19241349},{"date":"2026-06-18","current":-0.622732,"twenty":-0.976812,"median":-0.249506,"eighty":-0.063894,"marketCap":12097809},{"date":"2026-06-26","current":-0.648858,"twenty":-0.973101,"median":-0.48099,"eighty":-0.063975,"marketCap":12605356},{"date":"2026-07-02","current":-0.63248,"twenty":-0.972665,"median":-0.489621,"eighty":-0.064208,"marketCap":12287192},{"date":"2026-07-10","current":-0.526495,"twenty":-0.969063,"median":-0.492107,"eighty":-0.064364,"marketCap":10228216},{"date":"2026-07-17","current":-0.517838,"twenty":-0.966661,"median":-0.498158,"eighty":-0.064364,"marketCap":10060044},{"date":"2026-07-24","current":-0.405536,"twenty":-0.966661,"median":-0.494812,"eighty":-0.064364,"marketCap":7878347},{"date":"2026-07-31","current":-0.344004,"twenty":-0.964259,"median":-0.491606,"eighty":-0.064453,"marketCap":6682960},{"date":"2026-08-07","current":-0.422508,"twenty":-0.960657,"median":-0.485822,"eighty":-0.064589,"marketCap":8208068},{"date":"2026-08-14","current":-0.470325,"twenty":-0.960657,"median":-0.476271,"eighty":-0.064613,"marketCap":9136996},{"date":"2026-08-21","current":-0.367186,"twenty":-0.958635,"median":-0.452257,"eighty":-0.064655,"marketCap":7918730}],"updateTime":1787641188896},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAW\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633802453","title":"Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2633802453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633802453?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA3J1VWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631720556","title":"OrbiMed Advisors acquires 597,729 Traws Pharma shares worth $998,207","url":"https://stock-news.laohu8.com/highlight/detail?id=2631720556","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631720556?lang=en_us&edition=fundamental","pubTime":"2026-04-29 09:42","pubTimestamp":1777426955,"startTime":"0","endTime":"0","summary":"OrbiMed Advisors disclosed an increase in its stake in Traws Pharma to 1,203,250 shares through an indirect holding.Filing showed purchase of 597,729 shares at USD 1.67 per share.OrbiMed also reported warrant positions covering up to 2,988,645 shares, with an exercise price of USD 1.67.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLycHS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OrbiMed Advisors acquires 597,729 Traws Pharma shares worth $998,207","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230792","title":"Traws Pharma Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230792?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:39","pubTimestamp":1776285576,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc reports results for the quarter ended December 31 - Earnings SummaryTraws Pharma Inc TRAW.OQ reported quarterly adjusted earnings of 63 cents per share for the quarter ended December ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL8N40Y244:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627823052","title":"Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2627823052","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627823052?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:25","pubTimestamp":1776284738,"startTime":"0","endTime":"0","summary":"Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 85.8 percent increase over losses of $(5.00) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51845479/traws-pharma-q4-eps-0-71-misses-0-69-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Traws Pharma Q4 EPS $(0.71) Misses $(0.69) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627965237","title":"Traws Pharma posts FY25 net income of $9.2 million; revenue rises to $2.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627965237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627965237?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:01","pubTimestamp":1776283319,"startTime":"0","endTime":"0","summary":"Traws Pharma swung to net income of USD 9.2 million, versus a net loss of USD 166.5 million a year earlier.Revenue climbed to USD 2.8 million; the increase was due to recognition of deferred revenue following termination of the Symbio license agreement.Operating loss narrowed to USD 17.9 million from USD 142.4 million.PIPE financing for up to USD 60 million closed April 15, including USD 10 million upfront, with additional proceeds tied to milestone-based and three-year warrants.Cash and cash equivalents totaled USD 3.8 million at Dec. 31, 2025; financing and existing cash expected to fund operations into Q1 2027, including planned Phase 2a single-dose influenza human challenge trial for tivoxavir marboxil in Q2 2026 pending MHRA approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL89wgFv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","TRAW","IE00BGHQF748.EUR","NDAQ","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627770281","title":"Traws Pharma Announces up to $60 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627770281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627770281?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA5FJNRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627284887","title":"Traws Pharma Inc - Financing Advances Co's Influenza Program Through a Human Challenge Trial for Tivoxavir Marboxil in United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2627284887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627284887?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA5FJNRR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627848982","title":"Press Release: Traws Pharma Announces Up to $60 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627848982","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627848982?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:15","pubTimestamp":1776255300,"startTime":"0","endTime":"0","summary":"-- Financing led by Sirenia Capital Management LP advances Traws Pharma's. influenza program through a human challenge trial for tivoxavir marboxil. \"We are pleased to announce this financing and the support of existing and new investors,\" said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. \"The capital from this financing positions us to advance our influenza program through a human challenge trial in the UK while preserving access to additional capital as we achieve key development milestones.\". The financing was completed on April 15, 2026, with funding thereunder expected April 16, 2026, subject to the satisfaction of customary closing conditions. The terms of the financing are described in more detail in the Company's current report on Form 8-K to be filed in connection with the financing.Citizens JMP Securities, LLC and Tungsten Advisors LLC  acted as co-placement agents.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627228128","title":"Traws Pharma Inc - Announces Pricing of Private Placement for 6 Mln Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627228128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627228128?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:05","pubTimestamp":1776254716,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40Y07A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627281190","title":"Traws Pharma prices unregistered $10 million PIPE at $1.67 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627281190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627281190?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:03","pubTimestamp":1776254627,"startTime":"0","endTime":"0","summary":"Traws Pharma announced a PIPE private placement expected to raise USD 10 million in gross proceeds at closing.Deal priced at USD 1.67 per share through sale of common stock or pre-funded warrants.Milestone-based Series A and Series B warrants could add about USD 20 million in gross proceeds if exercised.Series C warrant could add up to USD 30 million in gross proceeds if exercised over a three-year term.Proceeds earmarked to advance influenza program through a UK human challenge trial for tivoxavir marboxil.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securiti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL67rwhD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192165","title":"Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626192165?lang=en_us&edition=fundamental","pubTime":"2026-04-09 02:46","pubTimestamp":1775673991,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 3 for CFO Charles Nolan Parker, dated July 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLGbKRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624455849","title":"Traws Pharma delays annual report filing, seeks 15-day extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2624455849","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624455849?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990789,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 12b-25 to delay its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Filing delay tied to additional time needed to assess impact of potential financing on financial statements, including going-concern disclosures.Management reported no financing agreement in place as it works to address Nasdaq minimum stockholders’ equity requirement.Company expects to file Form 10-K within 15-day extension period allowed under SEC rules.Preliminary results point to revenue of $2.8 million; net income seen at about $9.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLb6NVn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622297758","title":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622297758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622297758?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:32","pubTimestamp":1774614726,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview Traws Pharma Inc TRAW.OQ TRAW.O is expected to  show a fall in quarterly revenue when it reports  results on March 30 (est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612400625","title":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400625","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400625?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:17","pubTimestamp":1771507073,"startTime":"0","endTime":"0","summary":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold** Shares of Traws Pharma TRAW.O down 20.81% at $1.58 premarket** Co says the U.S. FDA placed on clinical hold its investigational new drug application for tivoxavir marboxil, a single oral tablet for prevention of seasonal influenza** Adds that FDA flagged concerns \"with the mutagenicity data package\" for drug in application** Also says it filed the application to allow the government's biomedical research unit to fully review its bid for inclusion in the strategic stockpile for avianflu treatment** Clinical hold does not directly impact ongoing and planned studies outside of the United States; working to mitigate issue in clinical development plan - TRAW  ** TRAW shares up 74.3% YTD       ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612140749","title":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612140749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612140749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:58","pubTimestamp":1771505921,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid-Eligible And Ineligible Covid-19 Patients Feb 19 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA COMPLETES ANALYSIS OF ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612059402","title":"Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612059402","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612059402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504217,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. reported completion of its clinical analysis from a 90-patient, open-label Phase 2 study evaluating ratutrelvir, an investigational oral ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID in mild-to-moderate COVID-19 patients, including a separate single-arm cohort of PAXLOVID-ineligible patients. The company said the analysis found fewer treatment-related adverse events and no viral rebound events in ratutrelvir-treated patients, with equivalent time to sustained symptom resolution versus PAXLOVID; in PAXLOVID-ineligible patients, it reported a shorter time to symptom resolution compared with PAXLOVID. The company also provided preclinical and development updates on tivoxavir marboxil tablets for once-monthly influenza prophylaxis, including plans for a PK study under an open IND in Australia and preparations for a human influenza prophylaxis challenge study in the UK. The ratutrelvir results were presented as completed in the announcement; no future present","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL41fzpr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","NDAQ","BK4007","LU2210149790.SGD","SG9999014013.SGD","TRAW","BK4585","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612540274","title":"Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=2612540274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612540274?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612402749","title":"Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2612402749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612402749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612060402","title":"Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2612060402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612060402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":79,"code":"91000000","status":"200"}]}}